Combined inhibition of MCL1 and BCL-2 with AMG 176 and venetoclax induces anti-tumor effects in primary patient samples and models of acute myeloid leukemia

被引：0
|
作者：
Caenepeel, Sean R. [1 ]
Osgood, Tao [1 ]
Belmontes, Brian [1 ]
Sun, Jan [1 ]
Cajulis, Elaina [1 ]
Wei, Andrew [2 ]
Coxon, Angela [1 ,3 ]
Canon, Jude [1 ]
Hughes, Paul [1 ]
机构：
[1] Amgen Inc, Thousand Oaks, CA 91320 USA
[2] Alfred Hosp, Melbourne, Vic, Australia
[3] Monash Univ, Melbourne, Vic, Australia
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-3972
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3972
引用
收藏
页数：2
相关论文
共 40 条
  • [1] Calaspargase-Pegol-Mknl Combined with BCL-2 and MCL-1 Inhibition for Acute Myeloid Leukemia
    Bollino, Dominique
    Ma, Xinrong
    Tighe, Kayla M.
    Casildo, Andrea
    Richard, Katharina
    Passaniti, Antonino
    Carter-Cooper, Brandon
    Strovel, Erin T.
    Emadi, Ashkan
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (23)
  • [2] Eradication of Acute Myeloid Leukemia Is Enhanced By Combined Bcl-2 and Mcl-1 Targeting
    Teh, Tse-Chieh
    Nguyen, Nhu-Y
    Glaser, Stefan
    Moujalled, Donia
    Pomilio, Giovanna
    Huang, David C. S.
    Guthridge, Mark
    Wei, Andrew H.
    BLOOD, 2014, 124 (21)
  • [3] Superior Anti-Leukemic Effects of Combined Acid Ceramidase and Bcl-2 Inhibition in Acute Myeloid Leukemia
    Ung, Johnson
    Tan, Su-Fern
    Shaw, Jeremy
    Fox, Todd
    Kester, Mark
    Feith, David
    Loughran, Thomas, Jr.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S211 - S212
  • [4] Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models
    Christian Lehmann
    Thomas Friess
    Fabian Birzele
    Anna Kiialainen
    Markus Dangl
    Journal of Hematology & Oncology, 9
  • [5] Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models
    Lehmann, Christian
    Friess, Thomas
    Birzele, Fabian
    Kiialainen, Anna
    Dangl, Markus
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
  • [6] AML Blasts Intrinsic Interferon Production Causes Resistance to Venetoclax in Human Acute Myeloid Leukemia Via Upregulation of MCL1, BCL2A1 and BCL-XL
    Dubois, Josephine
    Wu, Kai
    King, Darren
    Zheng, Xianing
    Ma, Qianyi
    Bedi, Karan
    Li, Jun
    Malek, Sami N.
    BLOOD, 2024, 144 : 4151 - 4152
  • [7] Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia
    Moujalled, Donia M.
    Pomilio, Giovanna
    Ghiurau, Corina
    Ivey, Adam
    Salmon, Jessica
    Rijal, Sewa
    Macraild, Sarah
    Zhang, Lan
    Teh, Tse-Chieh
    Tiong, Ing-Soo
    Lan, Ping
    Chanrion, Maia
    Claperon, Audrey
    Rocchetti, Francesca
    Zichi, Adrien
    Kraus-Berthier, Laurence
    Wang, Youzhen
    Hamovic, Ensar
    Morris, Erick
    Colland, Frederic
    Segal, David
    Huang, David
    Roberts, Andrew W.
    Maragno, Ana Leticia
    Lessene, Guillaume
    Geneste, Olivier
    Wei, Andrew H.
    LEUKEMIA, 2019, 33 (04) : 905 - 917
  • [8] Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia
    Zhang, Qi
    Riley-Gillis, Bridget
    Han, Lina
    Jia, Yanan
    Lodi, Alessia
    Zhang, Haijiao
    Ganesan, Saravanan
    Pan, Rongqing
    Konoplev, Sergej N.
    Sweeney, Shannon R.
    Ryan, Jeremy A.
    Jitkova, Yulia
    Dunner, Kenneth, Jr.
    Grosskurth, Shaun E.
    Vijay, Priyanka
    Ghosh, Sujana
    Lu, Charles
    Ma, Wencai
    Kurtz, Stephen
    Ruvolo, Vivian R.
    Ma, Helen
    Weng, Connie C.
    Ramage, Cassandra L.
    Baran, Natalia
    Shi, Ce
    Cai, Tianyu
    Davis, Richard Eric
    Battula, Venkata L.
    Mi, Yingchang
    Wang, Jing
    DiNardo, Courtney D.
    Andreeff, Michael
    Tyner, Jeffery W.
    Schimmer, Aaron
    Letai, Anthony
    Padua, Rose Ann
    Bueso-Ramos, Carlos E.
    Tiziani, Stefano
    Leverson, Joel
    Popovic, Relja
    Konopleva, Marina
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2022, 7 (01)
  • [9] Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia
    Donia M. Moujalled
    Giovanna Pomilio
    Corina Ghiurau
    Adam Ivey
    Jessica Salmon
    Sewa Rijal
    Sarah Macraild
    Lan Zhang
    Tse-Chieh Teh
    Ing-Soo Tiong
    Ping Lan
    Maia Chanrion
    Audrey Claperon
    Francesca Rocchetti
    Adrien Zichi
    Laurence Kraus-Berthier
    Youzhen Wang
    Ensar Halilovic
    Erick Morris
    Frédéric Colland
    David Segal
    David Huang
    Andrew W. Roberts
    Ana Leticia Maragno
    Guillaume Lessene
    Olivier Geneste
    Andrew H. Wei
    Leukemia, 2019, 33 : 905 - 917
  • [10] Long-Acting E. coli-Derived Asparaginase Potentiates the Anti-Leukemic Effect of BCL2 Inhibition, but Not MCL1 Inhibition, in Preclinical Models of Acute Myeloid Leukemia
    Bollino, Dominique
    Casildo, Andrea
    Ma, Xinrong
    Tighe, Kayla M.
    Carter-Cooper, Brandon
    Emadi, Ashkan
    BLOOD, 2023, 142
1234